India's Drug Development Lag: Regulatory Bottlenecks Threaten Pharma Leadership

Indian Express - Opinion · 10 Apr 2026 · 2 min read
Prelims · Science and technology Mains · GS3 Science and technology High relevance

India's clinical trial approval delays (up to 2 years vs 30 days in US) are crippling its potential in novel drug development despite being the 'pharmacy of the world', with AI-driven medicine acceleration making regulatory reforms urgent.

Key points

Clinical trial approval delays in India take up to 2 years compared to 30 days in the US and near-instant approvals in China under investigator-initiated trials, placing Indian firms at a competitive disadvantage.

Generative AI is compressing drug development timelines from years to months, yet India's regulatory bottlenecks prevent leveraging its strengths in computer science and biologics expertise.

India conducts fewer than 40 Phase I clinical trials annually versus 800+ in US and 1,000+ in China, primarily due to centralized review by single Subject Expert Committees (SECs) under CDSCO.

[GS3-Economy] The $50 billion Indian pharma industry's revenue trails single US firms like Merck ($64 billion), highlighting the revenue gap between generic manufacturing and novel drug development.

The 2023 Biopharma SHAKTI initiative aims to strengthen CDSCO but may be insufficient given AI's acceleration of drug discovery pipelines.

Decentralized SEC model proposed would allow hospitals/research institutes to approve trials with CDSCO notification, mirroring Australia's 30-year successful framework without compromising safety.

This connects to GS2-Governance as it demonstrates how outdated regulatory architectures hinder India's strategic sectors despite global best practice models being available.

[GS3-S&T] AI-driven personalized medicine for cancer/autoimmune diseases could democratize healthcare but requires agile trial frameworks to prevent therapeutic brain drain abroad.

Way Forward: Implement decentralized SEC registration for Phase I/II trials with mandatory multidisciplinary composition, adopt Australia's parallel review model, and integrate AI-specific trial protocols under CDSCO's revised rules.

Key terms

Investigator-Initiated Trials

Research studies where physicians/scientists rather than companies design and conduct clinical trials. China's use of this framework bypasses regulatory approval for early-phase trials, offering a comparative model for UPSC governance questions on balancing innovation speed with patient safety.

CDSCO

The Central Drugs Standard Control Organization is India's national regulatory body for pharmaceuticals and medical devices, functioning under the Ministry of Health. It approves clinical trials, imports, and manufacturing licenses under the Drugs and Cosmetics Act, 1940. UPSC relevance stems from its role in balancing drug safety with innovation promotion, a recurring governance challenge.

Phase I Clinical Trials

Initial human testing of novel drugs on small groups (20-100) to evaluate safety, dosage, and side effects. UPSC relevance lies in its strategic importance for India's biotech self-reliance and the tension between precautionary regulation and global competitiveness in pharmaceutical innovation.

Biopharma SHAKTI

A 2023 budget initiative to strengthen India's biopharmaceutical sector through regulatory modernization, research funding, and infrastructure development. UPSC relevance includes its role in achieving Atmanirbharta in critical healthcare technologies and positioning India in the $1.5 trillion global biopharma market.